WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 47.50
-1.34 (-2.74%)
Sep 10, 2026, 4:08 PM HKT
WuXi Biologics Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Buy" and an average price target of $57.72. The average 1-year stock price forecast is 21.52% higher than the current stock price, while the lowest is $30.88 (-34.99%) and the highest is $79.20 (+66.74%).
Price Target: $57.72 (+21.52%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for WuXi Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 16 | 17 | 17 | 16 | 16 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 5 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 25 | 26 | 26 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Zhongtai Securities No rating | Zhongtai Securities | Buy Maintains $61.35 | Buy | Maintains | $61.35 | +29.16% | Sep 5, 2026 |
| UBS | UBS | Buy Reiterates $51.10 → $62.00 | Buy | Reiterates | $51.10 → $62.00 | +30.53% | Sep 1, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $48.00 → $60.00 | Buy | Maintains | $48.00 → $60.00 | +26.32% | Aug 28, 2026 |
| Jefferies | Jefferies | Buy Maintains $60.00 | Buy | Maintains | $60.00 | +26.32% | Aug 27, 2026 |
Unknown Analyst Citi No rating | Citi | Buy Maintains $42.00 → $62.00 | Buy | Maintains | $42.00 → $62.00 | +30.53% | Aug 27, 2026 |
Financial Forecast
Revenue This Year
25.70B
from 21.79B
Increased by 17.92%
Revenue Next Year
30.70B
from 25.70B
Increased by 19.48%
EPS This Year
1.55
from 1.33
Increased by 16.32%
EPS Next Year
1.85
from 1.55
Increased by 19.78%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.